Genedrive Share News (GDR)

(Sharecast News) - Molecular diagnostics company Genedrive has been successful with its tender to Public Health England (PHE) under Lot 1 of the National Microbiology Framework for diagnostic goods and services, it announced on Monday.
The AIM-traded firm said the tender was opened in November, and sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of diagnostic goods and services, covering clinical laboratory diagnostic testing services.

It said the award of a framework contract was not exclusive to the company, nor was it a guarantee of orders, however it would allow participating authorities to issue call-off orders for products in the future.

All of Genedrive's currently-available and CE-marked products fall within the framework agreement, being the Genedrive 96 SARS-CoV-2 kit, the Genedrive HCV ID kit and the Genedrive MT-RNR1 ID kit.

"We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts," said chief executive officer David Budd.

"This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues."

At 1146 BST, shares in Genedrive were up 9.18% at 73.15p.